Dr Lisberg on Emerging Post-Osimertinib Treatment Options in EGFR-mutant NSCLC
Aaron Lisberg, MD, discusses ongoing and future efforts to expand effective treatment options for patients with osimertinib-resistant, EGFR-mutant non–small cell lung cancer.
Lung Responses to Atezolizumab/Bevacizumab Linked With OS in HCC and Pulmonary Metastasis
Second-Line Regorafenib Demonstrates Safety in Advanced HCC, Irrespective of Prior Treatment
First-line Toripalimab Plus Sorafenib Elicits Responses in Unresectable Hepatocellular Carcinoma
Data for Luspatercept Highlight Evolving Treatment Landscape in Lower-Risk MDS
2 Clarke Drive Cranbury, NJ 08512